In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...
TITAN signed a Memorandum of Agreement to explore the commercial deployment of Carbon Upcycling's low-carbon production technology. The collaboration is part of TITAN's agenda to double sales of low carbon products between 2022 and 2026 and the ultimate ambition to reach net zero by 2050. We continue to remain optimistic on TITAN's prospects in the US given the recent tariff negotiations and because only one third of Titan America's sales is imported in the US (10% tariff). Additionally, the US ...
Below our feedback notes written at the occasion of our annual Benelux Local Champions Conference that took place on 27 May 2025 at our historic building at Grand Place Brussels. This event offered the possibility to have one-on-one meetings and/or small group meetings with the following Benelux companies and their top management & IR: ACKERMANS & VAN HAAREN | AHOLD DELHAIZE | AKZONOBEL | ARCADIS | AZELIS | CORBION | GBL | LOTUS BAKERIES | MELEXIS | PROXIMUS | SOFINA | UMICORE
This conference book is your guide to our annual Benelux Local Champions Conference set to take place on Tuesday, 27 May 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or small group meetings with the following Benelux companies and their top management & IR. ACKERMANS & VAN HAAREN | AGEAS | AHOLD DELHAIZE | AKZONOBEL | ARCADIS | AZELIS | CORBION | GBL | KBC GROUP | LOTUS BAKERIES | MELEXIS | PROXIMUS | SOFINA | UMIC...
1Q underlying EBITDA declined by 14%, being 3% above consensus and 4% above our forecast. FY25 underlying EBITDA of at least € 1.4bn (roughly flat vs FY24) is reiterated although excludes potential tariffs and FX impacts. We remind that Syensqo is looking to divest Oil&Gas and Aroma in an effort to create shareholder value. We still appreciate Syensqo for its solid market positions, strong balance sheet (1.4x leverage) and solid mid to long term growth potential. Valuation is clearly discounted ...
Bekaert saw 1Q sales decline by 3% which was in line with consensus and 1% better than our forecast. Bekaert reiterated FY25 guidance calling for flat sales while it slightly lowered uEBIT margin guidance from ‘at least flat' to ‘stable', with our and consensus forecasts at respectively +0.3pp and +0.1pp. The gradually improving portfolio profile, very compelling valuation (EV/EBITDA25e of 3.9x) and ongoing support from the €200m share buyback program prompt us to maintain our BUY rating and € 5...
After a weak start of the year with a 6% decline in adjusted EBITDA in 1Q25, Solvay now expects FY25 adjusted EBITDA to land in the lower half of the previously given guidance range of € 1.0-1.1bn and we have set our new forecast close to the bottom end of this range. Weak macro conditions, which is mainly visible in soda ash, are for the moment more than offsetting the good progress with efficiency improvement measures. With current EBITDA generation, almost all FCF is absorbed to pay the high ...
Tessenderlo and Darling Ingredients announced the intention to combine their gelatin & collagen businesses in a joint venture, in which Tessenderlo would have a 15% stake. In light of the difficult market conditions, we welcome the combination which will lead to a gelatin & collagen powerhouse with a global market share of 35-40%. We still appreciate Tessenderlo for the sizeable free cash flow generation and maintain our Accumulate rating for now.
Ontex is a mix of two tales, ie a mature European business which is a private label market leader in most of its activities whilst its US activities have growth potential on the back of its challenger status and much lower private label penetration. A weak start of the year, intensified competition from A-label brands and limited visibility on the mid term upside from the US business prompt us to become a bit more cautious and lower our target price from € 12 to € 10. Given the significant upsid...
Despite (expected) 1Q top line weakness, ABI delivered a better than expected organic EBITDA performance, up 7.9% y/y. ABI reiterated FY25 guidance of 4-8% organic EBITDA growth which is in line with mid term guidance. We still see ABI as the undisputed leader in the beer space, with leading market shares in many markets, ongoing digitization and premiumization trends allowing to generate healthy free cash flows. Valuation remains attractive with EV/EBITDA25e at 9.2x and FCF yield25e at 7.7% and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.